AU2021377609A1 - Antibodies for opioid treatments - Google Patents

Antibodies for opioid treatments Download PDF

Info

Publication number
AU2021377609A1
AU2021377609A1 AU2021377609A AU2021377609A AU2021377609A1 AU 2021377609 A1 AU2021377609 A1 AU 2021377609A1 AU 2021377609 A AU2021377609 A AU 2021377609A AU 2021377609 A AU2021377609 A AU 2021377609A AU 2021377609 A1 AU2021377609 A1 AU 2021377609A1
Authority
AU
Australia
Prior art keywords
seq
antibody
amino acid
cdr
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021377609A
Other languages
English (en)
Other versions
AU2021377609A9 (en
Inventor
Paul T. BREMER
Kim D. Janda
Bin Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU2021377609A1 publication Critical patent/AU2021377609A1/en
Publication of AU2021377609A9 publication Critical patent/AU2021377609A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Addiction (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021377609A 2020-11-10 2021-11-08 Antibodies for opioid treatments Pending AU2021377609A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063111699P 2020-11-10 2020-11-10
US63/111,699 2020-11-10
PCT/US2021/058459 WO2022103700A1 (en) 2020-11-10 2021-11-08 Antibodies for opioid treatments

Publications (2)

Publication Number Publication Date
AU2021377609A1 true AU2021377609A1 (en) 2023-06-08
AU2021377609A9 AU2021377609A9 (en) 2024-09-26

Family

ID=81601678

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021377609A Pending AU2021377609A1 (en) 2020-11-10 2021-11-08 Antibodies for opioid treatments

Country Status (10)

Country Link
US (1) US20230399418A1 (https=)
EP (1) EP4244256A4 (https=)
JP (1) JP7839789B2 (https=)
KR (1) KR20230107301A (https=)
CN (1) CN116745318A (https=)
AU (1) AU2021377609A1 (https=)
CA (1) CA3200523A1 (https=)
IL (1) IL302673A (https=)
MX (1) MX2023005032A (https=)
WO (1) WO2022103700A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3267132A1 (en) * 2022-09-09 2024-03-14 Regents Of The University Of Minnesota ANTIBODIES DIRECTED AGAINST FENTANYL AND ITS ANALOGUES AND THEIR METHODS OF USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808822A (en) * 2006-04-14 2008-02-16 Amgen Inc Erythropoietin receptor agonists
WO2013095091A2 (en) * 2011-11-17 2013-06-27 Aimm Therapeutics B.V. Rsv g protein specific antibodies
AU2017345786B2 (en) * 2016-10-21 2024-08-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2018140821A1 (en) * 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
EP3880698A4 (en) * 2018-11-14 2022-11-30 RubrYc Therapeutics, Inc. MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF

Also Published As

Publication number Publication date
WO2022103700A1 (en) 2022-05-19
MX2023005032A (es) 2023-05-16
CN116745318A (zh) 2023-09-12
KR20230107301A (ko) 2023-07-14
US20230399418A1 (en) 2023-12-14
EP4244256A4 (en) 2024-12-25
IL302673A (en) 2023-07-01
CA3200523A1 (en) 2022-05-19
JP2023548603A (ja) 2023-11-17
AU2021377609A9 (en) 2024-09-26
JP7839789B2 (ja) 2026-04-02
EP4244256A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
JP6114326B2 (ja) 組織因子経路阻害因子に対する抗体
JP6437922B2 (ja) Ｂｃｍａ抗原結合タンパク質
JP7665098B2 (ja) 多重特異性抗体およびその使用
JP7607564B2 (ja) Ｐｍｅｌ１７に対する抗体及びその結合体
CN110022903B (zh) Met抗体药物缀合物
KR102132604B1 (ko) 비형 간염 표면 항원에 대한 항체 및 그의 용도
CN113412124A (zh) Baff-r双特异性t细胞衔接子抗体
JP7839789B2 (ja) オピオイド治療用抗体
CN114728180A (zh) 使用抗FcRn抗体治疗温性自身免疫性溶血性贫血的方法
US20220348687A1 (en) Dosing for anti-tryptase antibodies
RU2841257C1 (ru) Антитела для лечения опиоидной зависимости
TW202108631A (zh) 一種抗ｃｄ４７抗原結合蛋白及其應用
JP2024534004A (ja) 抗トリプターゼ抗体のための投与量
JP2024505195A (ja) 抗ｐｄｇｆ－ｂ抗体及び肺動脈高血圧症（ｐａｈ）を治療するための使用方法
CN115197323A (zh) 一种sn38抗体或其抗原结合片段及其应用
AU2022303422B2 (en) Anti-gfral antibody and application thereof
WO2024109709A1 (en) Ph-dependent anti-egfr antibodies for treatment of solid tumors
KR20260046391A (ko) 항-ror1 단백질 항체 및 이의 접합체
WO2024044722A1 (en) Drip-antibodies and use thereof
HK40112252A (en) Antibodies to pmel17 and conjugates thereof
HK40067775A (en) Dosing for anti-tryptase antibodies
WO2024025940A1 (en) Sars-cov-2 antibodies and bispecific antibodies
HK40068854A (en) Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies

Legal Events

Date Code Title Description
SREP Specification republished